Venus Remedies has approved a final dividend of ₹10 per equity share for the financial year ended March 31, 2026. The decision came at the company’s 37th Annual General Meeting, held on August 20, 2026.
The ₹10 payout equals 100% of the share’s ₹10 face value. It also marks an important change for the company, as Venus Remedies has resumed dividend payments after more than ten years. The move comes after a sharp rise in revenue and profit during FY26.
For shareholders, the dividend is a direct return from the company. At the same time, the payout gives a clear signal about the management’s confidence in the company’s cash position and future business prospects.
The record date for the dividend was August 7, 2026. Shareholders whose names appeared in the company’s records on that date were eligible for the payout. The dividend is subject to the usual tax rules and payment terms.
Saransh Chaudhary Gets Key Leadership Role
A major part of the AGM was the appointment of Saransh Chaudhary as Executive Director, also known as Whole-Time Director, of Venus Remedies.
His five-year term started on May 26, 2026. He will receive annual pay of ₹93.00 lakh, which includes bonus and other benefits.
Saransh Chaudhary already serves as Chief Executive Officer of Venus Medicine Research Centre, or VMRC. He also has a key role in the company’s global critical care and consumer healthcare business. His new position gives him a larger role in the company’s overall leadership and business plans.
The appointment is important because research and new products form a major part of Venus Remedies’ long-term business plan. The company has a strong focus on critical care medicines, specialty products and research.
His wider role may help the company connect its research work with its commercial plans. It may also support the company’s plans for new products and a stronger presence in global markets.
Strong FY26 Financial Results
The leadership change and dividend decision came after a strong FY26 for Venus Remedies.
Consolidated revenue from operations rose to ₹769.60 crore in FY26 from ₹652.89 crore in FY25. That represents growth of about 17.9% over the previous year.
Total income also rose to ₹782.18 crore from ₹668.84 crore. Total expenses stood at ₹648.02 crore in FY26, compared with ₹606.93 crore a year earlier.
The biggest change came at the profit level. Consolidated profit before tax rose to ₹134.16 crore from ₹61.91 crore. Net profit reached ₹102.78 crore, compared with ₹45.31 crore in FY25.
This means net profit more than doubled in one year. The rise was close to 127% on a year-on-year basis.
EBITDA also showed a sharp rise. It reached ₹159.86 crore in FY26 against ₹84.48 crore in FY25. Basic earnings per share rose to ₹76.89 from ₹33.89.
These numbers show that the company did not rely only on higher sales. Profit growth was much faster than revenue growth, which points to a better profit mix and stronger operating performance.
Q4 Also Showed Strong Growth
The final quarter of FY26 added more support to the full-year results.
Consolidated net profit for Q4 rose to ₹47.49 crore from ₹21.00 crore in the same quarter of the previous year. Revenue increased to ₹259.40 crore from ₹197.66 crore.
EBITDA also rose to ₹68.37 crore from ₹35.77 crore. The EBITDA margin improved to 25.86% from 18.10%.
These figures show a clear rise in both sales and profitability during the quarter. They also helped the company close FY26 with much stronger results than FY25.
Early FY27 Results Remain Strong
The positive trend has also continued into the first quarter of FY27.
Venus Remedies reported consolidated net profit of ₹22.97 crore for Q1 FY27, up 139.27% from ₹9.60 crore in the same quarter last year. Revenue from operations rose 30.38% year on year to ₹178.86 crore.
The company also saw a major rise in its operating EBITDA margin. It improved to 19.10% from 7.66% in the year-ago quarter.
This early FY27 performance is important because it gives investors a fresh view of the company after the strong FY26 results. It suggests that the sharp rise in profit was not limited to one quarter.
Other Board Changes Approved
The AGM also approved several other board-related resolutions.
Dr. (Mrs.) Manu Chaudhary received approval for reappointment as Joint Managing Director for another five years from October 1, 2026. Her annual remuneration was set at ₹153.50 lakh.
Dr. Gurminder Singh Bedi was appointed as a Non-Executive Independent Director for a five-year term from May 26, 2026.
Dr. (Mrs.) Savita Gupta was also proposed for reappointment as an Independent Non-Executive Director for a second consecutive term. Her new term is set to end on December 28, 2031.
The company also made changes to its Memorandum of Association and Articles of Association. The changes aim to align the company’s documents with the Companies Act, 2013, and its present business structure.
All 12 AGM Resolutions Passed
Venus Remedies said all 12 resolutions placed before shareholders at the AGM were passed with the required majority.
The resolutions covered the adoption of standalone and consolidated audited financial statements for FY26, dividend approval, director appointments and reappointments, and changes to key company documents.
However, some public institutions reportedly voted against certain proposals related to director appointments and changes to the company’s corporate documents. The resolutions still received the required support and were approved.
What This Means for Investors
The latest developments give Venus Remedies a stronger profile than it had a year ago.
The return of the dividend is positive for shareholders because it adds a direct cash return after a long gap. The ₹10 dividend also comes at a time when the company has reported a large rise in profit and cash generation.
The appointment of Saransh Chaudhary is another key point. His existing work at VMRC gives him a close connection with the company’s research side. His new executive role may help Venus Remedies place more focus on research, critical care medicines and international business.
Still, investors need to watch whether the high profit growth can continue. FY26 net profit reached ₹102.78 crore from ₹45.31 crore, so the base for future comparisons is now much higher.
The next few quarters will therefore matter a lot. Revenue growth, margins, new product launches, exports and cash flow will be important measures of the company’s progress.
A New Phase for Venus Remedies
Venus Remedies enters FY27 with strong financial results, a return to dividend payments and a wider leadership structure.
The ₹10 final dividend rewards shareholders after more than a decade without a payout. At the same time, the appointment of Saransh Chaudhary places a senior research and healthcare executive in a broader company role.
With FY26 revenue at ₹769.60 crore, net profit at ₹102.78 crore and EBITDA at ₹159.86 crore, the company has set a high base for its next phase.
The key test now is simple: can Venus Remedies maintain this growth while also build a stronger pipeline of medicines and expand its global business? The answer over the next few quarters will decide how meaningful this new phase becomes for the company and its shareholders.
ALSO READ: BigBloc Construction Q1 FY27 Results Show a Clear Turnaround
